Sentences with phrase «on pharmaceutical stocks»

Concerns that a Hillary Clinton administration would impose greater price regulation on drug companies had put a damper on pharmaceutical stocks for more than a year.

Not exact matches

In 2015, Ackman, the founder of hedge fund Pershing Square, announced his multi-billion dollar bet on Valeant Pharmaceuticals (vrx); he proceeded to lose nearly his entire investment, or $ 7.7 million every day for about two years, as Valeant stock sank 95 %.

Valeant Pharmaceuticals signage is displayed on a monitor on the floor of the New York Stock Exchange before the opening bell on March 21, 2016.

HOUSTON, April 20, 2018 (GLOBE NEWSWIRE)-- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the closing of its previously announced underwritten public offering of 9,200,000 shares of its common stock, including 1,200,000 shares sold pursuant to the underwriters» full exercise of their option to purchase additional shares, at a public offering price of $ 7.50 per share.

As news emerges of Amazon considering a big push into pharmaceuticals, CNBC's Jim Cramer endorsed one of his favorite drugmakers, Celgene, after its stock fell off a cliff on Thursday.

On a single - stock basis, Alexion Pharmaceuticals, Wynn Resorts, Lam Research, and Helmerich & Payne were the biggest winners, each adding at least 4.1 %.

BOSTON, April 20 (Reuters)- Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $ 25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene - silencing technology used to develop drug treatments.

HOUSTON, April 17, 2018 (GLOBE NEWSWIRE)-- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $ 7.50 per share.

Left, who has gained notoriety for successful bets against stocks such as Valeant Pharmaceuticals, explained that his rapid change of view on Twitter came as a result of the growing scrutiny surrounding social media and how companies handle users» personal information.

HOUSTON, April 16, 2018 (GLOBE NEWSWIRE)-- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that it has commenced an underwritten public offering of 7,000,000 shares of its common stock.

Valeant Pharmaceuticals was on an acquisition spree before accounting problems brought down its stock.

Meanwhile, health care stocks closed higher on Friday recovering from remarks made earlier this week by President - elect Donald Trump that pharmaceuticals were «getting away with murder.»

Pharma and biotech stocks swooned recently (the S&P Pharmaceuticals Select Industry Index is down 25 % in the last three months), largely on concerns about greater drug price regulation.

Pharmaceuticals and biotech are heavily represented on the list of the top 15 stocks by 5 - year total return.

It's no secret we've been on the opposite side of Bill Ackman's Pershing Square Capital on many recent stock picks, such as Herbalife (HLF), Mondelez (MDLZ), and, most notably, Valeant Pharmaceuticals (VRX).

John also sits on the Board of Strongco Corp, traded on the Toronto Stock Exchange as SQP and DelMar Pharmaceuticals, which is traded on OTCQX as DMPI.

Yulia has a diverse experience of managing legal teams and projects in investments, telecommunication, metal production and pharmaceuticals, including corporations listed on NASDAQ, Hong Kong Stock exchange and Moscow Stock exchange.

Caribou (CBOU), GT Solar (SOLR), which was featured in my June 3rd update, EasyLink Services (ESIC), Pharmacyclics (PCYC) and SciClone Pharmaceuticals (SCLN), featured in the May 17th list, are all repeat stocks appearing on this week's list.

Recently, we did so with a swing trade in Onyx Pharmaceuticals ($ ONXX), which enabled us to score a 10 % gain on the price of the stock over just a 3 - day holding period.

The iShares ETF is the largest covering the sector, tracking a set of biotechnology and pharmaceutical stocks that trade on the Nasdaq stock market.

Stocking up on some over-the-counter pharmaceutical creams, consuming more fiber for softer stools, and taking regular sitz baths should help.

Any newcomer will have to come to terms not only with the most dismal NCI budget scenario in 3 decades but also with stringent new rules on owning pharmaceutical stock; and because this is a presidential appointment, the director might have less than 2 years to serve.

It could have a dramatic impact on productivity, which in turn could have a major impact on the valuation of pharmaceutical stocks,» he said.

These risks and uncertainties include, among others, those relating to our ability to obtain sufficient financing to continue as a going concern, the outcome of the review of the continued listing of our common stock on The Nasdaq Stock Market, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8stock on The Nasdaq Stock Market, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8Stock Market, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.

Dollar Bill plans a big short position on a pharmaceutical company stock, but not everyone at Axe Cap approves.

• You profit from stocks that are very different than anything you could find on the TSX — including top pharmaceuticals and tech stocks.

While the SEC and the IRS are not completely clear on what a «substantially similar stock» means exactly, to be on the safe side, it is important that if stock A was a stock in the pharmaceutical industry, you don't purchase an identical stock from an identical pharmaceutical company (stock B) within that 30 - day window.

Start your stock research process with this new feature designed to identify investing opportunities based on topics that matter to you — ranging from pharmaceuticals to AI and beyond.

For our recent report on a penny stock with big potential but a good deal of risk as well, read BioLine partners with leading pharmaceutical.

The Agios Pharmaceuticals, Inc. (AGIO) mid-term technical analysis below is based on the analysis of the recent price trend of the AGIO stock, changes in trading volume and money flow.

Posted in Activist Investors, Net Cash Stocks, Stocks, Tang Capital Partners, Vanda Pharmaceuticals Inc (NASDAQ: VNDA), tagged Activist investment, Liquidating Value, Net Cash Stock, Tang Capital Partners, Vanda Pharmaceuticals Inc (NASDAQ: VNDA) on March 12, 2009 4 Comments»

Since the date of the last filing on Schedule 13D, on November 7, 2008, Tang Capital Partners, LP purchased 560,000 shares of Vanda Pharmaceuticals, Inc.'s common stock through the open market for $ 0.8291 per share.

Posted in Activist Investors, Net Cash Stocks, Stocks, Tang Capital Partners, Vanda Pharmaceuticals Inc (NASDAQ: VNDA), tagged Activist investment, Net Cash Stock, Tang Capital Partners, Vanda Pharmaceuticals Inc (NASDAQ: VNDA) on April 30, 2009 5 Comments»

Posted in About, Activist Investors, Carl Icahn, Poison Pills, Stocks, tagged Activist investment, Amylin Pharmaceuticals Inc. (NASDAQ: AMLN), Carl Icahn on April 22, 2009 Leave a Comment»

Posted in Activist Investors, Net Cash Stocks, Stocks, Tang Capital Partners, Vanda Pharmaceuticals Inc (NASDAQ: VNDA), tagged Activist investment, Liquidating Value, Net Cash Stock, Tang Capital Partners, Vanda Pharmaceuticals Inc (NASDAQ: VNDA) on April 8, 2009 Leave a Comment»

Theratechnologies Inc. et al. v. 121851 Canada Inc. 2015 SCC 18 Securities Regulation Summary: Theratechnologies Inc. (Thera) was a pharmaceutical research and development company based in Montreal and listed on the Toronto Stock Exchange.

Represented a biotechnology company focused on novel pharmaceutical therapies that seek to exploit RNA editing and DNA editing enzymes, in negotiating a license into the company relating to its core technology, and represent the company with regard to the creation and maintenance of its stock option plan and other general legal matters.

US firms cash in on active pharmaceutical sector as Valeant agrees deal to acquire Salix's outstanding stock

The reports also indicate that investors are in fact buying Galaxy Digital's shares through a shell pharmaceutical company which will allow Novogratz's firm to be listed on a Canadian stock exchange without disclosing its financials.

Maintains medication inventory by checking pharmaceutical stock on - site to determine inventory level.

And most Americans need full time employment while at college, so they list folding tee - shirts at The Gap, or stocking shelves at Rite Aid on their resume, despite having majored in biomedical engineering and job hunting for work in pharmaceutical labs.

While Clinton, while campaigning, made known her desire to take on the pharmaceutical industry, the energy sector and financial services, stock in some of those categories may enjoy a bounce now that their legal paths forward are clearer.